SCHEMBL1973344

SCHEMBL1973344

NC(=NO)c1cccc(Oc2ccc3c(c2)S(=O)(=O)NCCN3)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNKS O95271 1/20 0.38
PARP15 Q460N3 1/20 0.38
PARP14 Q460N5 1/20 0.38
PARP10 Q53GL7 1/20 0.38
TNKS2 Q9H2K2 1/20 0.38
PARP2 Q9UGN5 1/20 0.38
GRIA2 P42262 9/20 0.37
LMNA P02545 1/20 0.36
GFER P55789 1/20 0.36
KMT2A Q03164 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
KDM1A O60341 2/20 0.33
HDAC8 Q9BY41 1/20 0.32
AKR1C3 P42330 1/20 0.32
MMP2 P08253 1/20 0.32
MMP9 P14780 1/20 0.32
ADAM17 P78536 1/20 0.32
F2 P00734 1/20 0.32
F10 P00742 1/20 0.32
FURIN P09958 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1973340 0.88 LMNA (0.36) TNKSPARP15PARP14PARP10TNKS2
SCHEMBL1973359 0.88 LMNA (0.36) TNKSPARP15PARP14PARP10TNKS2
SCHEMBL1972444 0.84 AKR1C3 (0.50) TNKSPARP15PARP14PARP10TNKS2
SCHEMBL756185 0.81 KEAP1 (0.44) TNKSPARP15PARP14PARP10TNKS2
SCHEMBL1970207 0.80 MMP3 (0.41) GRIA2HDAC8MMP2MMP9ADAM17
SCHEMBL1967915 0.80 GRIA2 (0.53) GRIA2MMP2MMP9ADAM17
SCHEMBL1973863 0.80 MEN1 (0.44) PARP10GRIA2KMT2AL3MBTL1F2
SCHEMBL2809179 0.78 GRIA2 (0.57) GRIA2
SCHEMBL1979031 0.78 GRIA2 (0.41) GRIA2MMP2MMP9
SCHEMBL1969371 0.77 GRIA2 (0.39) GRIA2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8236790-B2 Benzothiadiazepine compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATORIES SERVIER (FR) 2012-08-07 US disclosed
EP-2246339-B1 Derivatives of benzothiazepine and their use as modulators of AMPA and NMDA receptors SERVIER LAB (FR) 2011-06-22 EP disclosed
EP-2246339-A1 Derivatives of benzothiazepine and their use as modulators of AMPA and NMDA receptors Les Laboratoires Servier (FR) 2010-11-03 EP disclosed
US-20100240635-A1 Benzothiadiazepine compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2010-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240635-A1 Benzothiadiazepine compounds, a process for their preparation and pharmaceutical compositions containing them GRIN1, GRIN2B, GRIN3A TNKS 2162/4885PARP15 1067/4885PARP14 1541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.